Results 221 to 230 of about 109,968 (264)
Some of the next articles are maybe not open access.
Pharmacology of Chimeric Antigen Receptor–Modified T Cells
Annual Review of Pharmacology and Toxicology, 2021Cell-based immunotherapies using T cells that are engineered to express a chimeric antigen receptor (CAR-T cells) are an effective treatment option for several B cell malignancies. Compared with most drugs, CAR-T cell products are highly complex, as each cell product is composed of a heterogeneous mixture of millions of cells.
Edward Z, Song, Michael C, Milone
openaire +2 more sources
The Future of Chimeric Antigen Receptor T Cell Therapy
Hematology/Oncology Clinics of North America, 2023Over the last 10 years CAR T cell therapies have been shown to be transformative for B- and plasma-cell malignancies, however the field is only beginning to realize the potential benefit to patients of such therapies. Over the next 10 years it is expected that advances will be made in durable response rates for patients with B/plasma cell malignancies;
openaire +2 more sources
A review of chimeric antigen receptor T-cells in lymphoma
Expert Review of Hematology, 2019Introduction: Immunotherapy has revolutionized the treatment of cancer. Antibodies, antibody drug conjugates, and bispecific antibodies have improved outcomes in various cancers especially lymphomas. Chimeric antigen receptor T cell (CAR-T) is a step forward in the immunotherapy paradigm for the treatment of Lymphomas.
Jennifer Kelly Anderson, Amitkumar Mehta
openaire +2 more sources
Chimeric antigen receptor T-cell therapy for glioblastoma
Translational Research, 2017Chimeric antigen receptor (CAR) T-cell therapy has shown great promise in the treatment of hematological disease, and its utility for treatment of solid tumors is beginning to unfold. Glioblastoma continues to portend a grim prognosis and immunotherapeutic approaches are being explored as a potential treatment strategy.
Analiz Rodriguez +2 more
openaire +2 more sources
Chimeric Antigen Receptors for T-Cell Based Therapy
2012The Chimeric Antigen Receptor (CAR) consists of an antibody-derived targeting domain fused with T-cell signaling domains that, when expressed by a T-cell, endows the T-cell with antigen specificity determined by the targeting domain of the CAR. CARs can potentially redirect the effector functions of a T-cell towards any protein and nonprotein target ...
Cheadle, Eleanor J. +10 more
openaire +3 more sources
Chimeric antigen receptor T‐cell therapy toxicities
British Journal of Clinical Pharmacology, 2020Cancer immunotherapy has greatly advanced in recent years, with chimeric antigen receptor (CAR) T cells emerging as an innovative technology that harnesses the immune system to fight malignant diseases. These genetically engineered T‐cells have shown encouraging results for B‐cell lymphoid malignancies and are now being explored for other cancer types.
Uri Greenbaum +7 more
openaire +2 more sources
Chimeric Antigen Receptor T Cells in Hematologic Malignancies
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017Patients with B‐cell hematologic malignancies who progress through first‐ or second‐line chemotherapy have a poor prognosis. Early clinical trials with autologous anti‐CD19 chimeric antigen receptor (CAR) T cells have demonstrated promising results for patients who have relapsed or refractory disease.
Brandon R, Shank +5 more
openaire +2 more sources
Chimeric Antigen Receptor T Cells in Multiple Myeloma
Hematology/Oncology Clinics of North America, 2023Multiple myeloma is the second most common hematological malignancy with an approximate incidence of up to 8.5 cases per 100,000 persons per year. Over the last decade, therapy for multiple myeloma has undergone a revolutionary change. Chimeric antigen receptor (CAR) T-cell therapy has played a major role in this evolution.
Parth, Shah, Adam S, Sperling
openaire +2 more sources
Chimeric antigen receptor T-cell therapy for melanoma
Expert Review of Clinical Immunology, 2021In recent years, chimeric antigen receptor (CAR) T cell therapy has emerged as a cancer treatment. After initial therapeutic success for hematologic malignancies, this approach has been extended for the treatment of solid tumors including melanoma.T cells need to be reprogramed to recognize specific antigens expressed only in tumor cells, a difficult ...
Azadehsadat Razavi +3 more
openaire +2 more sources
Chimeric Antigen Receptor T Cells for Cancer Immunotherapy
Journal of Clinical Oncology, 2015T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). The clinical benefit of CAR T cells has now been reported by several groups targeting the CD19 antigen in patients with hematologic malignancies.
Kevin J, Curran, Renier J, Brentjens
openaire +2 more sources